Late second-trimester abortions induced with mifepristone, misoprostol and oxytocin: a report of 428 consecutive cases

Contraception

Volumn 78, Issue 1, 2008, Pages 52-60

  Esteve, Josep Lluis Carbonell ^a   Gallego, Francisca Garcia ^b   Llorente, Margardell Pérez ^a   Bermúdez, Santiago Barambio ^c   Sala, Eugenia Sánchez ^a   González, Lidia Varela ^a   Texidó, Carlos Sánchez ^a  

^a Mediterranea Medica Clinic   (Spain)

^b Ginegranada Clinic   (Spain)

^c Gynecology Obstetric Service   (Spain)

Author keywords

Late second trimester abortion; Mifepristone; Misoprostol; Oxytocin

Indexed keywords

DILAPAN; MIFEPRISTONE; MISOPROSTOL; OXYTOCIN;

ADULT; ARTICLE; CESAREAN SECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DILATION AND EVACUATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; GESTATION PERIOD; GESTATIONAL AGE; HUMAN; PREGNANCY TERMINATION; SECOND TRIMESTER ABORTION; UTERUS RUPTURE;

ABORTION, INDUCED; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADULT; FEMALE; HUMANS; MIFEPRISTONE; MISOPROSTOL; OXYTOCIN; PREGNANCY; PREGNANCY TRIMESTER, SECOND; SAFETY; TREATMENT OUTCOME;

EID: 44949137135     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.02.016     Document Type: Article

References (27)

1. Interrupción voluntaria de embarazo. Datos definitivos del año 2005. Publicado en: Paseo del Prado 18, 28014, Madrid, por el Ministerio de Sanidad y Consumo de España.
2. The care of women requesting induced abortion. Evidence-based clinical guideline number 7. September 2004. Published by RCOG Press at the Royal College of Obstetricians and Gynaecologists. 27 Sussex Place, Regent's Park, London, England.
3. Grimes D.A., and Cates W. Complications from legally-induced abortion: a review. Obstet Gynecol Surv 34 (1979) 177-191
4. Peterson W.F., Berry F.N., Grace M.R., and Gulbranson C.L. Second-trimester abortion by dilatation and evacuation: an analysis of 11474 cases. Obstet Gynecol 62 (1983) 185-190
5. Bugalho A., Bique C., Almeida L., et al. The effectiveness of intravaginal misoprostol (Cytotec) in inducing abortion after eleven weeks of pregnancy. Stud Fam Plann 24 (1993) 319-323
6. Ho P.C., Ngai S.W., Liu K.L., Wong G.C.Y., and Lee S.W.H. Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. Obstet Gynecol 90 (1997) 735-738
7. Carbonell J.L.L., Rodríguez J., Delgado E., et al. Vaginal misoprostol 800 μg every 12 h for second-trimester abortion. Contraception 70 (2004) 55-60
8. Jain J.K., Kuo J., and Mishell Jr. D.R. A comparison of two dosing regimens of intravaginal misoprostol for second trimester pregnancy termination. Obstet Gynecol 93 (1999) 571-575
9. Ho P.C., Chan Y.F., and Law W. Misoprostol is as effective as gemeprost in termination second trimester pregnancy when combined with mifepristone: a randomized comparative trial. Contraception 53 (1996) 281-283
10. Rodger M.W., and Baird D.T. Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. BJOG 97 (1990) 41-45
11. Urquhart D.R., Bahzad C., and Templeton A.A. Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy. Hum Reprod 4 (1989) 202-203
12. Urquhart D.R., and Templeton A.A. The use of mifepristone prior to prostaglandin-induced midtrimester abortion. Hum Reprod 5 (1990) 883-886
13. Webster D., Penney G.C., and Templeton A. A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. BJOG 103 (1996) 706-709
14. Thong K.J., and Baird D.T. Induction of second trimester abortion with mifepristone and Gemeprost. BJOG 100 (1993) 758-761
15. Heikinheimo O., and Kekkonen R. Dose-response relationships of RU 486. Ann Med 25 (1993) 71-76
16. Campbell S., Warsof S.L., Little D., and Cooper D.J. Routine ultrasound screening for the prediction of gestational age. Obstet Gynecol 65 (1985) 613-620
17. Zieman M., Fong S.K., Benowitz N.L., et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 90 (1997) 88-92
18. Ashook P.W., and Templeton A. Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. BJOG 106 (1999) 706-710
19. Ashook P.W., Templeton A., Wagaarachchi P.T., and Flett G.M.M. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception 69 (2004) 51-58
20. Tang O.S., Chan C.C.W., Kan A.S.Y., and Ho P.C. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation. Hum Reprod 20 (2005) 3062-3066
21. Ngai S.W., Tang O.S., and Ho P.C. Randomized comparison of vaginal (200 μg every 3 h) and oral (400 μg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum Reprod 15 (2000) 2205-2208
22. Jain J.K., and Mishell D.R. A comparison of misoprostol with and without laminaria tents for induction of second trimester abortion. Am J Obstet Gynecol 175 (1996) 173-177
23. Carbonell J.L.L., Garcia Gallego F., Llorente M., et al. Vaginal vs. sublingual misoprostol with mifepristone for cervical priming in second-trimester abortion by dilation and evacuation: a randomized clinical trial. Contraception 75 (2007) 230-237
24. Carbonell J.L.L., Pino T., Sabina A., Abreu Y., and Sánchez C. Randomized, controlled clinical trial to evaluate the safety and efficacy of the administration of 25 μg of vaginal misoprostol against 50 μg of sublingual misoprostol for labor induction. Prog Obstet Ginecol 49 (2006) 369-379
25. Wing D.A., Lovvet K., and Paul R.H. Disruption of prior uterine incision following misoprostol for labor induction in women with previous cesarean delivery. Obstet Gynecol 91 (1998) 828-830
26. Chen M., Shih J.C., Chiu W.T., and Hsieh F.J. Separation of cesarean scar during second-trimester intravaginal misoprostol abortion. Obstet Gynecol 94 (1999) 840
27. Mazouni C., Provensal M., Porcu G., et al. Termination of pregnancy in patients with previous cesarean section. Contraception 73 (2006) 244-248